2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceAsk about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The theme of the whole document is to shorten the length of dual antiplatelet therapy.”
SBSorin BrenerCardiologist, New York Methodist Hospital
“We know that probably even less than [6 months] is ok, but I think that 6 months is a very good compromise.”
“One of the big questions among providers has been: What is the benefit, versus the harm, of long-term therapy? The guidelines suggest that longer term therapy may be reasonable for certain individuals, including those who are at lower risk of bleeding, because we are seeing further reduction of cardiovascular events with prolonged use of these drugs.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Levine et al. (2016) studied this question.